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NO is produced by a family of enzymes called the NO
synthases which includes the endothelial NO syn-
thase (eNOS), the neuronal NO synthase (nNOS) and
the inducible NO synthase (iNOS).
In endothelial cells, eNOS is constitutively ex-
pressed and the physiological role of endothelial-
derived NO seems to be the control of vascular tone
and the preservation of endothelial function (1). More-
over, NO causes suppressed platelet aggregation and
decreased monocyte and lymphocyte adhesion to
endothelium, suggesting that endothelium-derived
NO has antithrombotic activities and decreases infil-
tration of monocytes and lymphocytes into the intima
of arteries (2). In addition, NO reduces smoothmuscle
cell migration and proliferation. All these regulatory
functions of NO counteract atherogenesis and sug-
gest an anti-atherosclerotic effect of NO (3).
Several polymorphisms were detected in the eNOS
gene including two which may result in reduced
eNOS activity. The T-786C polymorphism in the eNOS
promoter region was shown to result in reduced tran-
scriptional activity of the minor C-786 allele (4). The
Asp298 eNOS protein of the Glu298Asp polymor-
phism in exon 7 showed a lower protein activity in
human placentas than the Glu298 eNOS protein and
preferential degradation in vitro (5, 6). However, other
recent in vitro studies questioned the functionality of
the Asp298 mutation in eNOS because there was no
difference in expression, protein activity or cellular
localization between the two eNOS variants (7, 8).
A recent meta-analysis suggests that there is an
association of the homozygous Asp298 eNOS geno-
type with atherosclerosis, but not of the homozygous
C-786 polymorphism (9). We decided to use a differ-
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ent approach to investigate the association of the
homozygous C-786 and the homozygous Asp298
eNOS genotypes with age-related disease. We sur-
mised that the frequency of any deleterious polymor-
phic allele will decrease in the older population if this
allele accelerates late onset disease but does not
affect reproductivity. In contrast, polymorphisms at
genetic loci that carry no selective disadvantage
should exhibit frequencies that remain constant
throughout life (10). If the C-786 or the Asp298 eNOS
genotype were significant risk factors for age-related
disease, then one would expect that the frequency of
the homozygous genotype of these alleles decreases
with age in the healthy population. Therefore, we
compared the genotype distribution of the two poly-
morphisms between younger (20–54 years) and older
(55–70 years) healthy volunteers in the Swiss
population.
A total of 400 healthy blood donors (aged 19–70
years) who gave informed consent to participate in
the study were randomly selected. Exclusion criteria
of the Swiss Red Cross were applied including coro-
nary artery disease (CAD), stroke, diabetes, claudica-
tion, untreated hypertension, anemia, infection,
cancer, chronic kidney disease, neurological disease
and others. Plasma creatinine (91.6"11.1 mmol/L for
males and 79.6"9.3 mmol/L for females) and total
cholesterol levels (5.6"1.1 mmol/L) were in the range
of the healthy Swiss population. The genotypes for
the T-786C and Glu298Asp eNOS polymorphisms
were analyzed by tetra-primer PCR assays (11).
The allele frequencies for the eNOS T-786C poly-
morphism were 57% (T-786) and 43% (C-786) and the
frequencies for the Glu298Asp polymorphism were
65.4% (Glu) and 34.6% (Asp). For both polymor-
phisms the genotype frequencies were in agreement
with those predicted by the Hardy-Weinberg equilib-
rium and are comparable to those in other Europeans
(12).
When we analyzed the Glu298Asp genotype
according to age and gender, using a recessive model
(Table 1), the homozygous Asp298 genotype was sig-
nificantly less frequent in males G55 years (oldest ter-
cile) than in males -55 years (5.95% vs. 16.35%,
ps0.015), whereas no notable difference was seen
between women older and younger than 55 years
(11.76% vs. 11.32%, ps0.935). To test whether this
difference is sensitive to the selected age cut-off, we
performed a secondary analysis of the data with an
age cut-off set to 60 years (oldest quintile). The fre-
quency of the homozygous Asp298 genotype further
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Table 1 Genotype frequencies for the Glu298Asp and the T-786C polymorphisms in eNOS according to age and gender.
Gender Age, years GluGlu and GluAsp AspAsp TT and TC CC
Male -55 (ns159) 133/159 26/159 131/159 28/159
83.65% 16.35%* 82.39% 17.61%
G55 (ns84) 79/84 5/84 72/84 12/84
94.05% 5.95%* 85.71% 14.24%
Female -55 (ns106) 94/106 12/106 87/106 19/106
88.68% 11.32% 82.08% 17.92%
G55 (ns51) 45/51 6/51 47/51 7/51
88.24% 11.76% 86.27% 13.73%
*Significant difference compared to GluGlu and GluAsp (ps0.015).
decreased to 5.08% in men G60 years (5.08% vs.
15.22%, ps0.027) but remained unchanged in women
G60 years (10.53% vs. 11.76%, respectively,
ps0.833). The genotype frequencies in the different
subgroups were all in agreement with those predicted
by the Hardy-Weinberg equilibrium.
Analysis of T-786C polymorphisms in eNOS accord-
ing to age and gender showed no significant differ-
ence in genotype frequency between the groups. The
CC genotype was slightly reduced at higher age
(G55 years) in males and females (Table 1) but was
similar when the age cut-off was set to 60 years (data
not shown).
This study shows that the homozygous Asp298
genotype in the eNOS gene is reduced in the older
healthy male population. A population in Hardy-Wein-
berg equilibrium for a particular polymorphism
should display genotype frequencies that remain sta-
ble throughout life (10). Any decrease in genotype fre-
quency with age in the healthy population is expected
only if the genotype is associated with disease which
develops past the age of reproduction. Atherosclero-
sis is such a disease, which in general does become
clinically overt in the fifth to sixth decade of life and
eNOS-dependent NO production is thought to be
atheroprotective through its preservation of endothe-
lial function.
The decrease in the homozygous Asp298 genotype
frequency in older men was observed in blood donors
who went through a selection process excluding vol-
unteers with various disorders. Therefore, combined
mortality and morbidity from various disorders
reduced the Asp298 genotype in this selected healthy
population. However, considering that eNOS is pre-
dominantly expressed in the vasculature and the
heart (13), it is most likely that mortality and morbi-
dity from cardiovascular disease are the underlying
cause for the reduction of the homozygous Asp298
eNOS genotype in older men. This raises the question
whether mortality and morbidity from atherosclerotic
disease can account for the observed reduction in
homozygous Asp298 genotypes in older males. In
Switzerland, the cumulative mortality from CAD in
men aged 20–54 years and 55–70 years is 0.17% and
1.0%, respectively, and in women the cumulative
mortality from CAD is 0.003% and 0.25%, respective-
ly. Morbidity data for atherosclerosis are not available
in Switzerland. However, we can estimate the preva-
lence for atherosclerosis. In men aged 20–54 years
and 55–70 years, two independent estimates yielded
a prevalence for atherosclerosis of 1.3–3.8% and
12.8–15.6%, respectively, and in women of 0.4–0.5%
and 4.5–6.3%, respectively. For both genders, the esti-
mated prevalence in the older groups is slightly lower
than the prevalence for CAD in the Framingham study
in the age group 55–64 years (14). Therefore, it
appears plausible that mortality and morbidity from
atherosclerotic disease may account for the signifi-
cant reduction of homozygous Asp298 genotypes in
older healthy males.
While we observed a decrease in homozygous
Asp298 genotypes in males, there was no difference
in genotype frequencies among women. Considering
that the average age in our male and female group
was similar, this may be explained by the low mor-
bidity rate for CAD in premenopausal women and the
approximate 10-year difference in mortality from CAD
between the sexes (15). Both of our estimates of prev-
alence for atherosclerosis in women also reflect this
difference between the sexes.
The study has several potential limitations. Because
this study is cross-sectional it is not possible to assess
the cause of the decrease in the Asp298 genotype
with advancing age. Since cardiovascular disease is
the leading cause of morbidity and death in subjects
over 60 years of age, and eNOS is implicated in vas-
cular function and integrity, the most likely cause of
the observed decrease in the homozygous Asp298
genotype with advancing age are cardiovascular dis-
eases. However, we cannot exclude that other dis-
eases associated with the homozygous Asp298
genotype also contribute to the decreased prevalence
of this genotype in older men. An additional limitation
is the limited power of our study. For example, a 50%
decrease in prevalence of the CC genotype in the old-
er age group is required for the T-786C polymorphism
to detect a difference with a power of 80% and smaller
decreases will be missed more frequently. Therefore,
we cannot exclude smaller real age-related decreases
in the genotype frequency with sufficient power.
In summary, our study in healthy volunteers shows
that the homozygous Asp298 eNOS genotype is
diminished in the older male population, whereas no
difference was found in allele frequency between the
younger and the older for the T-786C polymorphism.
These findings show that homozygous Asp298 eNOS
genotype is associated with disease that develops
past the age of reproduction.
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